Transactions related to vehicles include manufacturing, buying, selling, paying insurance(takaful), obtaining regular inspection, leasing a vehicle from banks, getting in an accident, engaging in a traffic violation, calculating price predictions and renting a vehicle. Many people perform transactions related to vehicles in their daily life; transportation authorities also perform vehicle transactions as part of managing vehicle fleets. But tracking these transactions is a challenging task. There are countrywide solutions that uses centralized systems. However, these solutions have problems with trust management, transparency, and access control. Therefore, we believe there is still room for integrated automation of various vehicle-related transactions. In this paper, we present a blockchainbased framework for vehicle tracking that incorporates the mentioned features. Moreover, blockchain is customized to enable usage control for additional transactions, such as inspection, renting and islamic insurance. The usage control model is integrated with IoT devices to continuously monitor the vehicles for certain conditions and remotely revoke access if needed [1]. The complete transaction set is recorded over an immutable ledger that provides trust, transparency and a complete history of record. In this paper, we also presents a prototype implementation of a permissioned blockchain, which will be made available under the GNUv3 General Public License. Performance analysis is performed on the newly proposed framework implementation over the permissioned blockchain to measure its adoption and suitability. INDEX TERMS Blockchain, decentralized applications, smart contracts, vehicle life cycle tracking VOLUME 4, 2016 This article has been accepted for publication in a future issue of this journal, but has not been fully edited. Content may change prior to final publication.

Objective:To determineRapid & End treatment response of patients treated with Sofosbuvir in Chronic Hepatitis C at tertiary care hospital.Methods:It was an observational study conducted at Memon Medical Institute from January 2016 to July 2017. The inclusion criteria for patients was 18 years of age or older, having chronic infection with HCV. Total=201 received sofosbuvir with or without interferon in our OPDs. Patients were categorized into Treatment naïve, treatment experienced and decompensated chronic liver disease. Pregnant patients and those not willing to participate were excluded. Initially genotyping and Quantitative HCV RNA test was done.Results:A total of 201 subjects were included in the study with mean age of the patients was 46.22± 14.41 years. Of 201 patients, n= 131 (65.2%) chronic hepatitis C, compensated cirrhosis n= 47(23.4%), and with decompensated cirrhosis n=23(11.4%). Most commonly genotype 3 n= 180 (89.6%) was present followed by genotype 1 n=9(4.5%), genotype 2 n=1(0.5%), genotype 4 n=1(0.5%). Of patients with genotype 3, 123 received dual therapy and 57 were given triple therapy. After one month of therapy HCV RNA by PCR, 200(99.5%) achieved RVR, 199(99%) achieved ETR and SVR achieved in 178(88.5%) while remaining 1 patient did not achieved RVR, 2 ETR and 12 patients did not achieved SVR and remaining 11 SVR lost follow up.Conclusion:Sofosbuvir has shown to be very effective andsuccessfulwith achievement of virological response with little or no resistance in all genotypes mainly genotype 3 treated in our study population. The promising results of our study will aid in better outcomes and therefore help in eradication of the virus.

Qualitative analysis is a cost-effective and sensitive method in patients treated with sofosbuvir for confirming RVR, especially in developing countries where patients are self-paying with significant financial constraints.